中国现代普通外科进展

参考文献

[1] Leon-Ferre RA, GoetzMP. Advances in systemic therapies for triple negative breast cancer[J]. BMJ, 2023, 381:e071674.

[2] Zhu S, Wu Y, Song B, et al. Recent advances in targeted strategies for triple-negative breast cancer[J]. J Hematol Oncol, 2023, 16(1):100.

[3] Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer[J]. Annu Rev Pathol, 2022, 17:181-204.

[4] Lammers SWM, Meegdes M, Vriens IJH, et al. Treatment and survival of patients diagnosed with high-risk HR+/HER2-breast cancer in the Netherlands:a population-based retrospective cohort study[J].ESMO Open, 2024, 9(5):103008.

[5] Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer[J]. N Engl J Med,2022, 387(3):217-226.

[6] Bardia A, Hurvitz SA, Tolanes SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16):1529-1541.

[7] Ascheid D, Baumann M, Pinnecker J, et al. A vascularized breast cancer spheroid platform for the ranked evaluation of tumor microenvironment-targeted drugs by light sheet fluorescence microscopy[J]. Nat Commun, 2024, 15(1):3599.

[8] Bardia A, Pusztal L, Albain K, et al. TROPION-Breast03:a randomized phase III global trial of datopotamab deruxtecan+/-durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy[J]. Ther Adv Med Oncol, 2024, 16:17588359241248336.

[9] Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer-expanded options, evolving needs[J].Nat Rev Clin Oncol, 2022, 19(2):91-113.

[10] Abraham JE, Pinilla K, Dayimu A, et al. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer[J]. Nature, 2024, 629(8014):1142-1148.

[11] Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival:a comprehensive meta-analysis[J]. Clin Cancer Res,2020, 26(12):2838-2848.

[12] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.

[13] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.

[14]张雪，董晓平，管雅喆，等.女性乳腺癌流行病学趋势及危险因素研究进展[J].肿瘤防治研究，2021,48(1):87-92.

[15]陈延君，刘晓菲，刘涵，等.中医药干预肿瘤相关巨噬细胞极化治疗乳腺癌的研究进展[J].中国现代普通外科进展，2023,26(9):741-744.

[16] Allemanl C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125):1023-1075.

[17] Barrios CH, Reinert T, Werutsky G. Global breast cancer research:moving forward[J]. Am Soc Clin Oncol Educ Book, 2018, 38:441-550.

[18] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J].CA Cancer J Clin, 2022, 72(1):7-33.

[19] Blondeaux E, Xie W, Carmisciano L, et al. Intermediate clinical endpoints in early-stage breast cancer:an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials[J]. EClinicalMedicine, 2024, 70:102501.

[20]中国抗癌协会乳腺癌专业委员会，中华医学会肿瘤学分会乳腺肿瘤学组.中国抗癌协会乳腺癌诊治指南与规范（2024年版）[J].中国癌症杂志，2024,33(12):1092-1187.

[21]王鹏，石乐明，黄薇，等.三阴性乳腺癌基因组与转录组全景图：亚型及治疗策略[J].科学新闻，2020,(2):45.

[22] Loibl S, Poortmans P, Morrow M, et al. Breast cancer[J]. Lancet,2021, 397(10286):1750-1769.

[23] Van Mackelenbergh MT, Seither F, Mobus V, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy-A metaanalysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients[J]. Eur J Cancer, 2022, 166:185-201.

[24] Golshan M, Loibl S, Wong SM, et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer:surgical results from the brightness randomized clinical trial[J]. JAMA Surg,2020, 155(3):e195410.

[25] Wang B, Sun T, Zhao Y, et al. A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer[J]. Nat Commun, 2022, 13(1):4025.

[26] Dubsky P, Pinker K, Cardoso F, et al. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer:the Lucerne toolbox[J]. Lancet Oncol,2021, 22(1):e18-e28.

[27] Van Maaren MC, De Munck L, Strobbe L JA, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands:A large population-based study[J]. Int J Cancer, 2019, 144(2):263-272.

[28]邵志敏.乳腺癌保乳手术的进展与评述[J].肿瘤防治研究，2018,45(5):269-273.

[29] Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer:long-term results of the randomized phaseⅢAPBI-IMRTFlorence Trial[J]. J Clin Oncol, 2020, 38(35):4175-4183.

[30] Poortmans PMP, Takanem S, Marta GN, et al. Winter is over:the use of artificial intelligence to individualise radiation therapy for breast cancer[J]. Breast, 2020, 49:194-200.

[31] Galimberti V, Cole BF, Viaie G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases(IBCSG 23-01):10-year follow-up of a randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(10):1385-1393.

[32] Zhu X, Chen L, Huang B, et al. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triplenegative breast cancer[J]. J Exp Clin Cancer Res, 2021, 40(1):122.

[33] Tee SR, Devang LA, Evoy D, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer[J]. Br J Surg, 2018, 105(12):1541-1552.

[34] Montero A, Cievide R, Poortmans P. When can we avoid postmastectomy radiation following primary systemic therapy[J]. Curr Oncol Rep, 2019, 21(12):95.

[35] Loibl S, O'shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer(BrighTNess):a randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(4):497-509.

[36] Poggio F, Bruzzong M, Ceppl M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer:a systematic review and meta-analysis[J]. Ann Oncol, 2018, 29(7):1497-1508.

[37] Zhang J, Yao L, Liu Y, et al. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer[J]. Int J Cancer,2021, 148(4):941-949.

[38] Early Breast Cancer Trialists'Collaborative G. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling:a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials[J]. Lancet, 2019,393(10179):1440-1452.

[39] Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups:the TNT Trial[J]. Nat Med, 2018, 24(5):628-37.

[40] Dieras V, Han HS, Kaufman B, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer(BROCADE3):a randomised, double-blind, placebo-controlled,phase 3 trial[J]. Lancet Oncol, 2020, 21(10):1269-1282.

[41] Masuda N, Lee SJ, Ohtanl S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 376(22):2147-2159.

[42] Wang X, Wang SS, Huang H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triplenegative breast cancer who had received standard treatment:the SYSUCC-001 randomized clinical trial[J]. JAMA, 2021, 325(1):50-58.

[43] Narod SA, Dent R. Triple-negative breast cancers[J]. Expert Rev Anticancer Ther, 2023, 23(10):1041-1043.

[44] Tutt ANJ, Garber JE, Kaufmanan B, et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer[J]. N Engl J Med, 2021, 384(25):2394-2405.

[45] Xu B, Sun T, Shi Y, et al. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations:a phaseⅡstudy[J]. Breast Cancer Res Treat,2023, 197(3):489-501.

[46] Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8):741-751.

[47] Shimizu T, Sands J, Yoh K, et al. First-in-human, phase I doseescalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer:TROPION-PanTumor01[J]. J Clin Oncol, 2023, 41(29):4678-4687.

[48] Schmid CP, Wysocki P, Ma C, et al. 379MO Datopotamab deruxtecan(Dato-DXd)+durvalumab(D)as first-line(1L)treatment for unresectable locally advanced/metastatic triple-negative breast cancer(a/mTNBC):Updated results from BEGONIA, a phaseⅠb/Ⅱstudy[J]. Ann Oncol, 2023, 34:S337.

[49] Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1):9-20.

[50] Schmid P, Cortes J, Pusztal L, et al. Pembrolizumab for early Triplenegative breast cancer[J]. N Engl J Med, 2020, 382(9):810-821.

[51] Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer(KEYNOTE-355):a randomised, placebo-controlled, double-blind,phase 3 clinical trial[J]. Lancet, 2020, 396(10265):1817-1828.

[52] Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nabpaclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22):2108-2121.

[53] Emens LA, Molinero L, Loi S, et al. Atezolizumab and nabpaclitaxel in advanced triple-negative breast cancer:biomarker evaluation of the impassion130 study[J]. J Natl Cancer Inst, 2021,113(8):1005-1016.

[54]魏昊，潘贇昊，牛瑞洁，等.三阴性乳腺癌浸润性淋巴细胞与PDL1表达的关系及相关生存分析（附视频导读）[J].中华内分泌外科杂志，2023,17(5):530-534.

[55] Khan SA, Zhao F, Goldstein LJ, et al. Early local therapy for the primary site in de novo stage IV breast cancer:results of a randomized clinical trial(EA2108)[J]. J Clin Oncol, 2022, 40(9):978-987.